feedback

Course Director

Harry P. Erba, MD, PhD
Harry P. Erba, MD, PhD

Duke University Medical Center
Durham, North Carolina

Faculty

Naval Daver
Naval Daver, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Courtney D. DiNardo
Courtney D. DiNardo, MD, MSCE

The University of Texas MD Anderson Cancer Center
Houston, Texas

Gail J. Roboz
Gail J. Roboz, MD

Weill Medical College of Cornell University
New York Presbyterian Hospital
New York, New York

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists and other clinicians involved in the management of AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML
  • Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy
  • Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features
  • Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported through educational grants from Bristol Myers Squibb and Jazz Pharmaceuticals, Inc.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Harry P. Erba, MD, PhD
Professor of Medicine
Director, Leukemia Program
Duke University Medical Center
Durham, North Carolina

Harry P. Erba, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Celgene Corporation; Covance Inc. (AbbVie Inc.); Daiichi-Sankyo Company, Limited; GlycoMimetics; ImmunoGen Inc.; Incyte; Jazz Pharmaceuticals, Inc.; Macrogen, Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Abbvie Inc.; Celgene Corporation; Daiichi-Sankyo Company, Limited; ImmunoGen Inc.; Incyte; Jazz Pharmaceuticals, Inc.; MacroGenics, Inc.; and Novartis Pharmaceuticals Corporation.

Faculty
Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Astellas; Bristol Myers Squibb Company; Daichi Sankyo Company Limited; F. Hoffmann-La Roche Ltd; Forty Seven, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen Inc.; Jazz Pharmaceuticals, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Syndax; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Astellas; Bristol Myers Squibb Company; Daichi Sankyo Company Limited; F. Hoffmann-La Roche Ltd; Fate Therapeutics; Forty Seven, Inc.; Genentech, Inc.; Hanmi Pharm.Co.,Ltd; ImmunoGen Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; and Trovagene, Inc.

Courtney D. DiNardo, MD, MSCE
Associate Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Courtney D. DiNardo, MD, MSCE, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Celgene; Daiichi Sankyo, Inc.; Immune-Onc Therapeutics; Notable Labs; and Novartis Pharmaceuticals Corporation.
Grant/Research Support from Abbvie, Agios Pharmaceuticals Inc.; Calithera; Celgene; Clear Creek Bio; and Daiichi Sankyo, Inc.

Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Medical College of Cornell University
NewYork Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Actinium Pharmaceuticals, Inc.; Agios Pharmaceuticals Inc.; Amphivena Therapeutics; Argenx; Array BioPharma; Astellas Pharma US, Inc.; AstraZeneca; Astex Therapeutics; Bayer; Celgene; Celltrion; Daiichi-Sankyo Company, Limited; Eisai Inc.; Epizyme; Helsinn; F. Hoffmann-La Roche/Genentech; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; MEI Pharma-IDMC Chair; Novartis Pharmaceuticals Corporation; Orsenix; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sandoz; Takeda Pharmaceuticals U.S.A., Inc.; and Trovagene.
Grant/Research Support from Cellectics.
Data Safety Monitoring Board for Abbvie Inc.; Actinium Pharmaceuticals, Inc.; Agios Pharmaceuticals Inc.; Amphivena Therapeutics; Argenx; Array BioPharma; Astellas Pharma US, Inc.; AstraZeneca; Astex Therapeutics; Bayer; Celgene; Celltrion; Daiichi-Sankyo Company, Limited; Eisai Inc.; Epizyme; Helsinn; F. Hoffmann-La Roche/Genentech; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; MEI Pharma-IDMC Chair; Novartis Pharmaceuticals Corporation; Orsenix; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sandoz; Takeda Pharmaceuticals U.S.A., Inc.; and Trovagene.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Natalie I. Vokes, MD
Stacy L. Sims, MSN, RN, CMCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.